A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition

• Published in: NPJ precision oncology Vol. 8; no. 1; p. 3
• Main Authors: Lenchner, Daniel S., Petrova, Zaritza O., Hunihan, Lisa, Ashtekar, Kumar D., Walther, Zenta, Wilson, Frederick H.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05-01-2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/575; 692/4028/67/1612/1350; Cancer Research; Cancer therapies; Case reports; Gene Therapy; Human Genetics; Internal Medicine; Kinases; Lymphatic system; Medicine; Medicine & Public Health; Metastasis; Mutation; Oncology; Patients; Tumors
• ISSN: 2397-768X; 2397-768X
• DOI: 10.1038/s41698-023-00490-w

EGFR tyrosine kinase inhibitors (TKIs) have transformed the treatment of EGFR-mutated non-small cell lung carcinoma (NSCLC); however, therapeutic resistance remains a clinical challenge. Acquired secondary EGFR mutations that increase ATP affinity and/or impair inhibitor binding are well-described mediators of resistance. Here we identify a de novo EGFR Y891D secondary alteration in a NSCLC with EGFR L858R. Acquired EGFR Y891D alterations were previously reported in association with resistance to first generation EGFR TKIs. Functional studies in Ba/F3 cells demonstrate reduced TKI sensitivity of EGFR L858R + Y891D, with the greatest reduction observed for first and second generation TKIs. Unlike other EGFR mutations associated with TKI resistance, Y891D does not significantly alter ATP affinity or promote steric hindrance to inhibitor binding. Our data suggest that the Y891D mutation destabilizes EGFR L858R, potentially generating a population of misfolded receptor with preserved signaling capacity but reduced sensitivity to EGFR inhibitors. These findings raise the possibility of protein misfolding as a mechanism of resistance to EGFR inhibition in EGFR-mutated NSCLC.